Key result
Tamoxifen cuts 24-h serum GH concentrations by ~31% versus placebo in late pubertal males.
Why the study?
The role of endogenous estrogens in the control of growth hormone secretion during male adolescence was unclear.
Does tamoxifen reduce growth hormone secretion in late pubertal males?
RCT (n=10)
Does tamoxifen reduce growth hormone secretion in late pubertal males?
Absolute Event Rate: 2.7% vs 3.9%
p-value: p=< 0.05
Short-term estrogen receptor blockade with tamoxifen reduces growth hormone secretion in late pubertal males, suggesting endogenous estrogens play a stimulatory role in the somatotropic axis during puberty.
Tamoxifen may suppress GH in late pubertal males receiving it; confirms endogenous estrogens stimulate the somatotropic axis.
The increase in GH production during the male adolescent growth spurt has been attributed to both androgen and estrogen receptor-mediated processes. To evaluate the role of endogenous estrogens in the control of GH secretion, we administered the estrogen receptor antagonist tamoxifen to 10 late pubertal males. Blood samples were obtained for GH determination at 10-min intervals on 2 occasions during the last 24 h of a 4-day course of either tamoxifen or placebo. Waveform-specific, multiple parameter deconvolution analysis was employed to assess GH secretory and elimination dynamics. Estrogen receptor blockade resulted in a significant (P < 0.05) diminution in mean 24-h serum GH concentrations, from 3.9 +/- 1.0 (placebo; mean +/- SEM) to 2.7 +/- 0.6 micrograms/L (tamoxifen). This was associated with a significant (P < 0.01) decline in the GH production rate [237 +/- 55 vs. 155 +/- 33 micrograms/L GH distribution volume (Lv).24 h]. Furthermore, this reduction in GH secretion was the result of significant decreases in both the maximal GH secretory rate (0.46 +/- 0.08 vs. 0.34 +/- 0.06 microgram/Lv.min; P < 0.01) and, to a smaller degree, GH secretory burst number (16 +/- 1 vs. 14 +/- 1/24 h; P < 0.05). There was also a trend toward reduced mass of GH secreted per burst (13.3 +/- 2.5 vs. 10.3 +/- 2.0 micrograms/Lv; P = 0.06). No significant alterations in either GH elimination t1/2 or GH secretory burst half-duration were observed during estrogen receptor antagonism. Tamoxifen treatment was associated with a significant (P < 0.05) decrease in plasma insulin-like growth factor-I concentrations. However, total and free testosterone, 17 beta-estradiol, insulin-like growth factor-binding protein-3, and pooled 24-h LH concentrations were not significantly changed by short term blockade of estrogen action. We postulate that endogenous estrogens play a facilitatory role in neuroendocrine control of the somatotropic axis during puberty in boys. Tamoxifen blocks this estrogen-dependent stimulation of GH secretion without altering the hormone elimination t1/2. Furthermore, we speculate that any stimulatory role of androgens on GH secretion is exerted primarily through the estrogen receptor after aromatization.
No takes yet. Share an insight, caveat, or question.
Metzger et al. (1994) conducted an RCT in Late pubertal males (n=10). Tamoxifen vs. Placebo was evaluated on mean 24-h serum GH concentrations (p=< 0.05). Tamoxifen significantly decreased mean 24-h serum GH concentrations from 3.9 to 2.7 micrograms/L compared to placebo in late pubertal males (P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: